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Abstract: VacA is a pore-forming toxin that has long been known to induce vacuolization in gastric
epithelial cells and to be linked to gastric disorders caused by H. pylori infection. Its role as a major
colonization and persistence determinant of H. pylori is less well-understood. The purpose of this
review is to discuss the various target cell types of VacA and its mechanism of action; specifically, we
focus on the evidence showing that VacA targets myeloid cells and T-cells to directly and indirectly
prevent H. pylori-specific T-cell responses and immune control of the infection. In particular, the ability
of VacA-proficient H. pylori to skew T-cell responses towards regulatory T-cells and the effects of Tregs
on H. pylori chronicity are highlighted. The by-stander effects of VacA-driven immunomodulation on
extragastric diseases are discussed as well.
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1. VacA Has Immunomodulatory and -Suppressive Activity on Various Cell Types of the
Mammalian Immune System that Ensure the Persistence of Helicobacter pylori in Its Host
The immunomodulatory and colonization-promoting activity of the vacuolating cytotoxin VacA of
H. pylori was discovered more than a decade after its vacuolating activity on epithelial cells and remains
much less well-understood. A study published in 2001 provided the first experimental evidence for a
critical role of VacA in mouse stomach colonization: VacA mutants were shown to be outcompeted
by the parental wild type strains in mixed infections and exhibited an ID50 that was more than two
orders of magnitude higher than that of the corresponding wild types in single infections [1]. This
finding has since been confirmed and extended in single infections with isogenic VacA null mutants in
the same or related strain backgrounds; one study found VacA mutants to colonize at significantly
lower levels [2], whereas, in another study, VacA mutants were recovered from <20% of infected mice
(relative to >90% for wild type) and at lower densities [3]. In humans, the majority of isolates express
some form of VacA, from alleles that vary substantially in sequence and expression level. A study
of 43 independent isolates—the most comprehensive study to date—revealed that all were positive
for the vacA gene, but only 28 (65%) expressed the corresponding protein and exhibited vacuolating
activity on HeLa cells in vitro [4]. Interestingly, genetic manipulation of the s and i regions (i.e., regions
that are highly polymorphic in human isolates) affects the ability of H. pylori strains to infect mice;
the s2i2 allele of VacA appears to promote murine colonization, whereas the (highly expressed and
highly cytotoxic) s1i1 allele does not [3]. This finding is particularly interesting, as the s1i1 allele
of VacA has been linked to gastric cancer and premalignant lesions in several studies [3,5,6]. One
important conclusion from the combined epidemiological and experimental studies is thus that the
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cytotoxic, tissue damage-inducing properties and the immunomodulatory properties of VacA are likely
genetically and functionally distinct; s2i2-expressing strains exhibit a clear phenotype upon deletion of
their vacA allele despite it encoding a non-cytotoxic version of the protein. It must be noted, however,
that VacA expression is not an absolute requirement for stomach colonization. Not only have human
isolates been identified that lack VacA expression as mentioned above [4], but other related Helicobacter
species such as H. felis and H. mustelae exhibit high-level gastric colonization in their respective host
species albeit lacking vacA alleles [7,8].
The putative immunomodulatory and -suppressive properties of H. pylori VacA have been
attributed to its profound effects on various types of immune cells. VacA is known to interact
with myeloid cells as well as lymphocytes. Three types of interactions have been identified and
studied in some detail. On the one hand, VacA has been reported to target professional phagocytes
and to affect phagocytic killing of H. pylori by interfering with endocytic pathways. On the other
hand, VacA is known to exploit the β2 integrin receptor to promote its uptake into human T-cells,
where it interferes with T-cell proliferation, clonal expansion, and cytokine production. Finally, a new
VacA-dependent mechanism of interference with normal functions of dendritic cells has recently been
identified, which promotes the priming and differentiation of regulatory T-cells at the expense of
effector T-cell differentiation. The evidence for all three immunomodulatory mechanisms is presented
below in three dedicated sections. The implications of the findings for vaccine development, as well as
for H. pylori eradication strategies and treatment decisions are discussed where appropriate, along with
the known involvement/role of VacA in the (prevention of) extragastric diseases. Overall, this review
is meant to give an up-to-date summary of the many facets of this important H. pylori colonization and
persistence determinant that pertain to immunomodulation, and its molecular and cellular targets at
the interface of the pathogen with the host immune system.
2. VacA Targets Phagocytes to Prevent Proper Phagosome Maturation, Antigen Processing and
Presentation, Intracellular Killing, and Cytokine Production
Multiple distinct mechanisms have been proposed to prevent or delay internalization of H. pylori
by phagocytes, particularly macrophages, and to interfere with proper phagosome maturation and
intracellular trafficking; several of these processes are believed to be dependent on VacA. H. pylori
actively prevents or at least delays its uptake by macrophages [9,10]. Once it is inside the macrophages,
H. pylori initially resides in single bacteria-containing phagosomes, which quickly fuse homotypically
into so-called megasomes containing multiple viable bacteria and resembling giant multivesicular
bodies [10]. This process of phagosome fusion appears to be specific for type I strains, i.e., VacA- and
Cag-PAI-positive strains [10], but could not be linked directly to either the Cag-PAI nor VacA using
mutant strains in a follow-up study [11]. Whether H. pylori remains alive for extended periods of time
in either murine and human monocytes or macrophages that have undergone phagosome fusion is not
entirely clear [10,11]. Another study has shown that H. pylori-containing phagosomes fail to mature and
instead resemble early endosomes that have resisted lysosome fusion; again, this process was specific
to type I strains and, in this case, are also dependent on VacA expression (Figure 1) [12]. Treatment
with recombinant IFN-γ enabled phagocytes to overcome their block in phagosome maturation and
to kill intracellular type I strains of H. pylori [12]. A more recent study has followed up on the earlier
observations using a co-infection model of murine bone-marrow-derived macrophages with H. pylori
as well as Lactobacillus acidophilus, a commensal organism found throughout the intestinal tract that
is known to promote Th1 polarization of T-cells. Whereas L. acidophilus exposure alone induced a
Th1-polarizing and-promoting response of BM-derived macrophages characterized by high expression
of IL-12 and IFN-β (such macrophages are also referred to as M1 macrophages), co-culture with
wild-type H. pylori strongly reduced the expression of these cytokines [13]. A VacA-deficient mutant
failed to interfere with L. acidophilus-induced cytokine expression in this manner. In a somewhat similar
experimental setup using bone-marrow-derived dendritic cells (BM-DCs), VacA-proficient H. pylori
effectively prevented the expression of DC maturation markers such as CD80 and CD86, as well as
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the expression and production of IL-12 upon LPS stimulation [2]. Whereas uninfected DCs readily
upregulated CD80 and CD86 when treated with E. coli LPS, and produced large amounts of IL-12,
TNF-α and IL-6, this TLR4-driven activation was strongly suppressed by wild-type H. pylori [2,14].
In contrast, VacA-deficient isogenic mutants in various H. pylori backgrounds failed to exhibit this
suppressive phenotype [2], strongly implying VacA as an immunomodulatory factor targeting DCs,
macrophages, or other professional phagocytes (Figure 1). The phenotype of macrophages or DCs that
have been exposed to VacA-proficient, but not -deficient, H. pylori is reminiscent of semi-mature cells,
characterized by high expression of MHC class II, but low expression of co-stimulatory molecules and
a low or absent production of inflammatory and Th1-polarizing cytokines. The recently published
observations on DCs [2] support and extend early work on VacA’s effects on antigen processing in
B-cells [15]. To test the possibility that VacA alters antigen processing taking place in pre-lysosomal
compartments, Molinari and colleagues used a model of antigen processing and presentation consisting
of tetanus toxoid-specific human CD4+ T-cells stimulated by autologous antigen-pulsed Epstein–Barr
virus-transformed B-cells. VacA was found to interfere with the proteolytic processing of the
tetanus toxin and toxoid by B-cells and to specifically inhibit the antigen presentation by newly
synthesized MHC class II, while leaving the presentation pathway dependent on recycling MHC
class II unaffected [15]. In conclusion, although professional phagocytes and antigen-presenting cells,
including B-cells, have been somewhat overlooked as potential VacA target cells, there is a considerable
amount of definitive evidence in support of strong immunosuppressive effects—preventing Th
cell-mediated immunity and persistent infection—on these cell types.
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Figure 1. VacA prevents phagosome maturation in professional antigen-presenting cells. Most
strains of H. pylori express the secreted virulence factors VacA to affect phagosome maturation and
lysosome fusion. The receptor for VacA on myeloid cells is not known. It has been proposed that
H. pylori-containing phagosomes fail to mature and instead resemble early endosomes that have
resisted lysosome fusion; this process appears to be specific to type I strains and is dependent on VacA
expression [12]. Treatment with recombinant IFN-γ allows phagocytes to overcome their block in
phagosome maturation and to kill intracellular type I strains of H. pylori.
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3. VacA Blocks T-Cell Activation and Effector Functions
Experimental studies conducted in the course of almost two decades using various rodent models
of H. pylori infection have shed light on the elements of the innate and adaptive immune system
required for immune-mediated control of H. pylori infections; many such studies were designed to
dissect the parameters and correlates of vaccine-induced protective immunity [16–20]. Whereas B-cells
and antibodies are clearly dispensable for H. pylori control [18], it is now clear that CD4+ effector
T-cells, and in particular Th1 and Th17-polarized T-effector cell subsets along with their signature
cytokines, are critical for proper control of this infection [16–20]. Interestingly, the same T-cell subtypes
have been implicated in initiating and promoting the immunopathological changes of the chronically
infected gastric mucosa that manifest histologically as atrophic gastritis, compensatory epithelial
hyperplasia, and intestinal metaplasia in experimentally infected animals and symptomatic human
carriers [21,22]. VacA, as well as another persistence factor of H. pylori, the γ-glutamyl-transpeptidase,
GGT, has been specifically implicated in the manipulation and inhibition of human T-cells. VacA
inhibits T-cell proliferation by interfering with the T-cell receptor/interleukin-2 signaling pathway at
the level of the Ca2+/calmodulin-dependent phosphatase calcineurin [23,24]. By preventing the nuclear
translocation of the T-cell transcription factor NF-AT, VacA inhibits the subsequent transactivation
of T-cell-specific immune response genes [23,24]. Follow-up studies have since identified β2 integrin
(CD18) as the receptor for VacA on human T-cells [25]; β2 integrin heterodimerizes with CD11a
on T-cells to form the transmembrane receptor LFA-1 (lymphocyte function-associated antigen-1).
H. pylori exploits the recycling of LFA-1 for VacA uptake [25] in a manner that depends on protein
kinase C-mediated serine/threonine phosphorylation of the β2 integrin cytoplasmic tail [26]. The
second H. pylori virulence determinant implicated in T-cell inhibition, the GGT enzyme, appears to
block T-cell function in a similar manner [27,28]. Like VacA, GGT is a secreted factor that most if not
all isolates of H. pylori encode and express. GGT blocks proliferation of T-cells through a mechanism
that involves the inhibition of cyclin-dependent kinase activity in the G1 phase of the cell cycle by the
disruption of the Ras signaling pathway [27,28].
4. VacA Promotes the Differentiation of Regulatory T-Cells over Effector T-Cells and Thereby
Ensures Persistent H. pylori Infection
In line with the ability of VacA-proficient strains of H. pylori to retain professional
antigen-presenting cells in a semi-mature state (i.e., high MHC class II, low CD80/CD86, low
pro-inflammatory cytokine production), several reports have focused on the downstream consequences
for T-cell priming. VacA-deficient mutants and purified VacA were both used to address the
type of T-cell responses, the predominant cytokines produced, and the consequences of these
immunological parameters for persistent H. pylori colonization and the T-cell-mediated responses to
other (non-Helicobacter-derived) antigens. The lower levels of colonization of VacA mutants relative to
their parental wild type was found to correlate with higher numbers of Th1 and Th17 cells, higher
expression of IFN-γ and IL-17 by restimulated mesenteric lymph node (MLN) single cell preparations,
and lower numbers of FoxP3+ CD25+ regulatory T-cells in MLNs [2]. The difference in T helper
cell responses, which are biased towards regulatory T-cell responses in the presence of VacA, was
attributed to VacA’s effects on DCs. DCs that were immunomagnetically purified based on their
CD11c expression from the MLNs of wild-type-infected mice induced FoxP3 and CD25 expression in
co-cultured naive CD4+ T-cells ex vivo [2]. This was not observed with DCs from uninfected animals or
from mice infected with a VacA mutant [2]. The defect of the VacA mutant in tolerizing dendritic cells
in vivo was also confirmed in in vitro settings, where BM-DCs co-cultured with the wild-type bacteria,
but not with various VacA mutants in several strain backgrounds, induced FoxP3 and CD25 expression
in co-cultured T-cells [2]. The semi-mature phenotype of DCs thus correlates with their ability to induce
Treg differentiation, as has been described in many other experimental settings [29]. The long-term
consequences of VacA deficiency are all related to the overshooting effector T-cell responses seen with
these mutants, as they cause more severe inflammation, atrophic gastritis, intestinal metaplasia, and
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epithelial hyperplasia than their corresponding wild-type strain [2]. This phenotype in the mouse
model is striking given the well known toxigenic activity of VacA on human mucosal epithelial cells,
but is well in line with its immunosuppressive and immunomodulatory properties.
H. pylori-VacA-induced Tregs not only ensure persistent H. pylori infection in the mouse model [30],
but also drive immune tolerance to non-related T-cell antigens. This has been shown in models of
allergen-induced asthma using ovalbumin or house dust mite allergens [2]. The induction of Tregs with
suppressive activity against allergen-specific T-cell responses depends on VacA, as VacA mutants fail to
suppress allergen-induced asthma (Figure 2) [2]. Furthermore, the adoptive transfer of MLN-derived
Tregs from wild-type-infected donors to naive recipients protects the recipients from allergic asthma;
this Treg-dependent protection is not seen with cells from VacA mutant-infected donors [2]. The
immunomodulatory activity of VacA was further shown to be retained in purified protein from culture
supernatants of H. pylori [31]. The s1m1 variant of VacA is readily secreted by bacteria growing in
liquid culture media, from which it can be purified in its oligomeric form [32]. Administration of
several doses of VacA protects efficiently against allergen-induced asthma, especially if the protein is
provided in the neonatal tolerance window [31]. This time frame constitutes a period in both mice
and humans in which immune tolerance to antigens is readily established [33]; therefore, it is perhaps
not surprising that VacA acts most potently during this time [31]. Active tolerization against allergens
using VacA requires its interaction with DCs, as mouse strains lacking IL-10 expression in the DC
compartment cannot be tolerized with VacA [31]. These results again speak in favor of selective
targeting of VacA to DCs (or at least CD11c-positive myeloid cells), where it exerts tolerance-promoting
activity. Further work is required to definitively show that VacA interacts with DCs in vivo, either in
the gastric mucosa or the draining lymph nodes, and that VacA-tolerized DCs are functionally different
from naive DCs.
Several studies have emphasized the role of (VacA-induced) Tregs in the H. pylori/host interaction
in both humans and experimentally infected mice. The experimental depletion of Tregs facilitates
clearance of H. pylori in infected animals [30,34,35] and enhances vaccine-induced protective immunity
in vaccinated mice [36]. The Treg-driven persistence of H. pylori requires T-cell-specific expression
of IL-10; in fact, IL-10´/´ mice and a strain lacking IL-10 expression exclusively in the CD4+ T-cell
compartment are capable of spontaneously controlling experimental infections [30,37–39]. The efficient
control or even clearance of H. pylori in Treg-depleted animals invariably comes at the price of enhanced
gastric immunopathology (gastritis and epithelial preneoplastic changes such as atrophy and intestinal
metaplasia). Interestingly, an analogous observation has been reported for human carriers, which
either accumulate large numbers of IL-10-producing, H. pylori-specific Tregs and are colonized heavily
(asymptomatic carriers), or develop gastric ulcers because their Treg response is inadequate [40]. In
summary, experimental studies in infected animals and observational studies in humans support a
critical role of Tregs in maintaining a benign interaction between H. pylori and its host, preventing
bacterial clearance on the one hand, and limiting immunopathology on the other.
Given the well-documented immunomodulatory activity of VacA on T-cells, myeloid cells, and
potentially other cells of the mammalian immune system, it comes as no surprise that vaccine
development efforts have focused on this molecule as a promising target of vaccination. In fact,
recombinantly produced VacA, along with two other highly immunogenic H. pylori proteins, CagA
and NAP, have not only been extensively tested in murine vaccine models [41] but also in humans.
A clinical phase I trial assessing the safety and immunogenicity of a vaccine consisting of the
three recombinant proteins, given intramuscularly with aluminium hydroxide as an adjuvant to
noninfected healthy subjects, concluded that this experimental vaccine demonstrated satisfactory
safety and immunogenicity profiles and produced both humoral immunity and antigen-specific
T-cell memory [42]. However, efficacy has not been documented in humans for a VacA-containing
vaccine. The potential of VacA as a vaccine antigen and its documented activity against allergic
asthma in experimental models of disease prevention clearly warrant further research into the
immunomodulatory properties of this multifunctional persistence determinant of H. pylori.
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Figure 2. H. pylori exerts immunomodulatory effects at extragastric sites. H. pylori exclusively inhabits
the gastric mucosa but has systemic immunomodulatory effects that manifest in the airways, lower
gastrointestinal tract, and possibly the skin. Gastric tissue-resident DCs presumably sample H. pylori
antigens locally at the site of infection and subsequently migrate to the stomach-draining and mesenteric
lymph nodes (MLNs), where they prime T-effector and regulatory T-cell responses. VacA is believed
to skew this process towards Treg differentiation [2]. MLN-derived, H. pylori-induced Tregs enter the
circulation and, due to cross-talk between the GI tract and lung immune systems, may accumulate
in both the gastric mucosa and the lung. According to current models, allergen-specific Th2 cells
in the lung are suppressed by H. pylori-induced Tregs via soluble mediators (such as IL-10) and
contact-dependent mechanisms (reviewed in [43]). Tregs further suppress Th1 and Th17 responses
directed against H. pylori in the gastric mucosa [30,44]. DC: dendritic cell; Th1/2/17: T-helper cell
subsets; Treg: regulatory T-cell. Please note that, due to space restrictions, the MLN shown here is
not in its correct anatomical location, which would be in the mesentery, linking the intestines to the
abdominal wall.
5. Conclusions
Despite being better known for its vacuolating and cytotoxic activity, VacA has also recently
received considerable attention for its immunomodulatory properties. A range of effects on several
types of immune cells has been attributed to VacA in vitro and in vivo; the protein’s ability to insert
into lipid bilayers to form anion-selective channels appears to be a prerequisite of both its cytotoxic
and immunomodulatory activity. Whether and how VacA targets immune cells in the gastric mucosa
remains to be determined; an in vivo tracking system using GFP- or otherwise tagged VacA would be
a highly useful tool in this respect. It is conceivable that VacA secreted from bacteria residing in the
gastric mucus, or in close proximity to gastric epithelial cells, is readily sampled by intraepithelial DCs
and macrophages that extend protrusions into the gastric lumen. It is less straightforward to envision
Toxins 2016, 8, 187 7 of 9
VacA targeting T-cells, which reside exclusively in the lamina propria. A direct interaction of VacA with
T-cells would require disruption of epithelial tight junctions and the subsequent loss of epithelial barrier
function, processes that are known to occur during H. pylori infection of polarized monolayers [45,46].
More evidence is needed from both naturally infected humans hosts as well as experimental animals to
better understand the immunological consequences of VacA-positive H. pylori infection. In particular,
more work is needed to clarify the differential cytotoxic and immunomodulatory activity of s1i1m1
VacA relative to its less toxigenic counterparts encoded by other alleles. Recent work on H. pylori
strains in which the endogenous allele was exchanged for one of two alternative, naturally occuring
alleles [3] to generate isogenic strains, differing only in the type of VacA they produce, represents a
step in the right direction and model for future work. The identification of a (putative) VacA receptor
on immune cells other than T-cells is also of great importance, as dendritic cells and macrophages
likely represent the first line of defence (and first target cell of VacA) encountered by H. pylori. A
better understanding of VacA’s target cells and mechanism of action will facilitate its targeting and
exploitation for new treatment and prevention strategies.
Acknowledgments: Work in the laboratory of A.M. is funded by the Swiss National Science foundation
(310030-143609 and BSCGIO 157841/1).
Author Contributions: A.M wrote the manuscript and A.D. provided the figures.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Salama, N.R.; Otto, G.; Tompkins, L.; Falkow, S. Vacuolating cytotoxin of Helicobacter pylori plays a role
during colonization in a mouse model of infection. Infect. Immun. 2001, 69, 730–736. [CrossRef] [PubMed]
2. Oertli, M.; Noben, M.; Engler, D.B.; Semper, R.P.; Reuter, S.; Maxeiner, J.; Gerhard, M.; Taube, C.; Muller, A.
Helicobacter pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence
and immune tolerance. Proc. Natl. Acad. Sci. USA 2013, 110, 3047–3052. [CrossRef] [PubMed]
3. Winter, J.A.; Letley, D.P.; Cook, K.W.; Rhead, J.L.; Zaitoun, A.A.; Ingram, R.J.; Amilon, K.R.; Croxall, N.J.;
Kaye, P.V.; Robinson, K.; et al. A role for the vacuolating cytotoxin, VacA, in colonization and
Helicobacter pylori-induced metaplasia in the stomach. J. Infect. Dis. 2014, 210, 954–963. [CrossRef] [PubMed]
4. Xiang, Z.; Censini, S.; Bayeli, P.F.; Telford, J.L.; Figura, N.; Rappuoli, R.; Covacci, A. Analysis of expression
of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be
divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin.
Infect. Immun. 1995, 63, 94–98. [PubMed]
5. Basso, D.; Zambon, C.F.; Letley, D.P.; Stranges, A.; Marchet, A.; Rhead, J.L.; Schiavon, S.; Guariso, G.;
Ceroti, M.; Nitti, D.; et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms.
Gastroenterology 2008, 135, 91–99. [CrossRef] [PubMed]
6. Rhead, J.L.; Letley, D.P.; Mohammadi, M.; Hussein, N.; Mohagheghi, M.A.; Eshagh Hosseini, M.;
Atherton, J.C. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is
associated with gastric cancer. Gastroenterology 2007, 133, 926–936. [CrossRef] [PubMed]
7. Arnold, I.C.; Zigova, Z.; Holden, M.; Lawley, T.D.; Rad, R.; Dougan, G.; Falkow, S.; Bentley, S.D.; Müller, A.
Comparative whole genome sequence analysis of the carcinogenic bacterial model pathogen Helicobacter felis.
Genome Biol. Evol. 2011, 3, 302–308. [CrossRef] [PubMed]
8. O'Toole, P.W.; Snelling, W.J.; Canchaya, C.; Forde, B.M.; Hardie, K.R.; Josenhans, C.; Graham, R.;
McMullan, G.; Parkhill, J.; Belda, E.; et al. Comparative genomics and proteomics of Helicobacter mustelae, an
ulcerogenic and carcinogenic gastric pathogen. BMC Genomics 2010, 11. [CrossRef] [PubMed]
9. Ramarao, N.; Gray-Owen, S.D.; Backert, S.; Meyer, T.F. Helicobacter pylori inhibits phagocytosis by professional
phagocytes involving type IV secretion components. Mol. Microbiol. 2000, 37, 1389–1404. [CrossRef] [PubMed]
10. Allen, L.A.; Schlesinger, L.S.; Kang, B. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis
and stimulate homotypic phagosome fusion in macrophages. J. Exp. Med. 2000, 191, 115–128. [CrossRef] [PubMed]
11. Rittig, M.G.; Shaw, B.; Letley, D.P.; Thomas, R.J.; Argent, R.H.; Atherton, J.C. Helicobacter pylori-induced
homotypic phagosome fusion in human monocytes is independent of the bacterial vacA and cag status.
Cell Microbiol. 2003, 5, 887–899. [CrossRef] [PubMed]
Toxins 2016, 8, 187 8 of 9
12. Zheng, P.Y.; Jones, N.L. Helicobacter pylori strains expressing the vacuolating cytotoxin interrupt phagosome
maturation in macrophages by recruiting and retaining taco (coronin 1) protein. Cell Microbiol. 2003, 5, 25–40.
[CrossRef] [PubMed]
13. Weiss, G.; Forster, S.; Irving, A.; Tate, M.; Ferrero, R.L.; Hertzog, P.; Frokiaer, H.; Kaparakis-Liaskos, M.
Helicobacter pylori VacA suppresses Lactobacillus acidophilus-induced interferon beta signaling in macrophages
via alterations in the endocytic pathway. MBio 2013, 4, e00609–e00612. [CrossRef] [PubMed]
14. Oertli, M.; Sundquist, M.; Hitzler, I.; Engler, D.B.; Arnold, I.C.; Reuter, S.; Maxeiner, J.; Hansson, M.; Taube, C.;
Quiding-Jarbrink, M.; et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific
immune tolerance, and asthma protection. J. Clin. Investig. 2012, 122, 1082–1096. [CrossRef] [PubMed]
15. Molinari, M.; Salio, M.; Galli, C.; Norais, N.; Rappuoli, R.; Lanzavecchia, A.; Montecucco, C. Selective
inhibition of ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J. Exp. Med. 1998, 187,
135–140. [CrossRef] [PubMed]
16. Akhiani, A.A.; Pappo, J.; Kabok, Z.; Schon, K.; Gao, W.; Franzen, L.E.; Lycke, N. Protection against
Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells.
J. Immunol. 2002, 169, 6977–6984. [CrossRef] [PubMed]
17. DeLyria, E.S.; Redline, R.W.; Blanchard, T.G. Vaccination of mice against H. pylori induces a strong Th-17
response and immunity that is neutrophil dependent. Gastroenterology 2009, 136, 247–256. [CrossRef]
[PubMed]
18. Ermak, T.H.; Giannasca, P.J.; Nichols, R.; Myers, G.A.; Nedrud, J.; Weltzin, R.; Lee, C.K.; Kleanthous, H.;
Monath, T.P. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection
in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 1998, 188,
2277–2288. [CrossRef] [PubMed]
19. Sayi, A.; Kohler, E.; Hitzler, I.; Arnold, I.; Schwendener, R.; Rehrauer, H.; Muller, A. The CD4+ T cell-mediated
IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk.
J. Immunol. 2009, 182, 7085–7101. [CrossRef] [PubMed]
20. Velin, D.; Favre, L.; Bernasconi, E.; Bachmann, D.; Pythoud, C.; Saiji, E.; Bouzourene, H.; Michetti, P.
Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model.
Gastroenterology 2009, 136, 2237–2246.e1. [CrossRef] [PubMed]
21. Shi, Y.; Liu, X.F.; Zhuang, Y.; Zhang, J.Y.; Liu, T.; Yin, Z.; Wu, C.; Mao, X.H.; Jia, K.R.; Wang, F.J.; et al.
Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and
contribute to pathology in mice. J. Immunol. 2010, 184, 5121–5129. [CrossRef] [PubMed]
22. Stoicov, C.; Fan, X.; Liu, J.H.; Bowen, G.; Whary, M.; Kurt-Jones, E.; Houghton, J. T-bet knockout prevents
Helicobacter felis-induced gastric cancer. J. Immunol. 2009, 183, 642–649. [CrossRef] [PubMed]
23. Gebert, B.; Fischer, W.; Weiss, E.; Hoffmann, R.; Haas, R. Helicobacter pylori vacuolating cytotoxin inhibits T
lymphocyte activation. Science 2003, 301, 1099–1102. [CrossRef] [PubMed]
24. Sundrud, M.S.; Torres, V.J.; Unutmaz, D.; Cover, T.L. Inhibition of primary human T cell proliferation by
Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc. Natl. Acad.
Sci. USA 2004, 101, 7727–7732. [CrossRef] [PubMed]
25. Sewald, X.; Gebert-Vogl, B.; Prassl, S.; Barwig, I.; Weiss, E.; Fabbri, M.; Osicka, R.; Schiemann, M.; Busch, D.H.;
Semmrich, M.; et al. Integrin subunit CD18 is the T-lymphocyte receptor for the Helicobacter pylori vacuolating
cytotoxin. Cell Host Microbe 2008, 3, 20–29. [CrossRef] [PubMed]
26. Sewald, X.; Jimenez-Soto, L.; Haas, R. PKC-dependent endocytosis of the Helicobacter pylori vacuolating
cytotoxin in primary T lymphocytes. Cell Microbiol. 2010, 13, 482–496. [CrossRef] [PubMed]
27. Gerhard, M.; Schmees, C.; Voland, P.; Endres, N.; Sander, M.; Reindl, W.; Rad, R.; Oelsner, M.; Decker, T.;
Mempel, M.; et al. A secreted low-molecular-weight protein from Helicobacter pylori induces cell-cycle arrest
of T cells. Gastroenterology 2005, 128, 1327–1339. [CrossRef] [PubMed]
28. Schmees, C.; Prinz, C.; Treptau, T.; Rad, R.; Hengst, L.; Voland, P.; Bauer, S.; Brenner, L.; Schmid, R.M.;
Gerhard, M. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase.
Gastroenterology 2007, 132, 1820–1833. [CrossRef] [PubMed]
29. Maldonado, R.A.; von Andrian, U.H. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol.
2010, 108, 111–165. [PubMed]
Toxins 2016, 8, 187 9 of 9
30. Arnold, I.C.; Lee, J.Y.; Amieva, M.R.; Roers, A.; Flavell, R.A.; Sparwasser, T.; Müller, A. Tolerance rather than
immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011, 140, 199–209.
[CrossRef] [PubMed]
31. Engler, D.B.; Reuter, S.; van Wijck, Y.; Urban, S.; Kyburz, A.; Maxeiner, J.; Martin, H.; Yogev, N.;
Waisman, A.; Gerhard, M.; et al. Effective treatment of allergic airway inflammation with Helicobacter
pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. Proc. Natl. Acad. Sci. USA
2014, 111, 11810–11815. [CrossRef] [PubMed]
32. Cover, T.L.; Blaser, M.J. Purification and characterization of the vacuolating toxin from Helicobacter pylori.
J. Biol. Chem. 1992, 267, 10570–10575. [PubMed]
33. Arnold, B.; Schuler, T.; Hammerling, G.J. Control of peripheral T-lymphocyte tolerance in neonates and
adults. Trends Immunol. 2005, 26, 406–411. [CrossRef] [PubMed]
34. Raghavan, S.; Fredriksson, M.; Svennerholm, A.M.; Holmgren, J.; Suri-Payer, E. Absence of CD4+CD25+
regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter
pylori-infected mice. Clin. Exp. Immunol. 2003, 132, 393–400. [CrossRef] [PubMed]
35. Rad, R.; Brenner, L.; Bauer, S.; Schwendy, S.; Layland, L.; da Costa, C.P.; Reindl, W.; Dossumbekova, A.;
Friedrich, M.; Saur, D.; et al. CD25+/FOXP3+ T cells regulate gastric inflammation and Helicobacter pylori
colonization in vivo. Gastroenterology 2006, 131, 525–537. [CrossRef] [PubMed]
36. Hitzler, I.; Oertli, M.; Becher, B.; Agger, E.M.; Müller, A. Dendritic cells prevent rather than promote immunity
conferred by a Helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology 2011, 141, 186–196.
[CrossRef] [PubMed]
37. Ismail, H.F.; Fick, P.; Zhang, J.; Lynch, R.G.; Berg, D.J. Depletion of neutrophils in il-10(´/´) mice delays
clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J. Immunol.
2003, 170, 3782–3789. [CrossRef] [PubMed]
38. Sayi, A.; Kohler, E.; Toller, I.M.; Flavell, R.A.; Muller, W.; Roers, A.; Muller, A. TLR-2-activated B cells
suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells.
J. Immunol. 2011, 186, 878–890. [CrossRef] [PubMed]
39. Matsumoto, Y.; Blanchard, T.G.; Drakes, M.L.; Basu, M.; Redline, R.W.; Levine, A.D.; Czinn, S.J. Eradication
of Helicobacter pylori and resolution of gastritis in the gastric mucosa of IL-10-deficient mice. Helicobacter
2005, 10, 407–415. [CrossRef] [PubMed]
40. Robinson, K.; Kenefeck, R.; Pidgeon, E.L.; Shakib, S.; Patel, S.; Polson, R.J.; Zaitoun, A.M.; Atherton, J.C.
Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.
Gut 2008, 57, 1375–1385. [CrossRef] [PubMed]
41. Del Giudice, G.; Malfertheiner, P.; Rappuoli, R. Development of vaccines against Helicobacter pylori. Exp. Rev.
Vaccines 2009, 8, 1037–1049. [CrossRef] [PubMed]
42. Malfertheiner, P.; Schultze, V.; Rosenkranz, B.; Kaufmann, S.H.; Ulrichs, T.; Novicki, D.; Norelli, F.;
Contorni, M.; Peppoloni, S.; Berti, D.; et al. Safety and immunogenicity of an intramuscular Helicobacter pylori
vaccine in noninfected volunteers: A phase I study. Gastroenterology 2008, 135, 787–795. [CrossRef] [PubMed]
43. Arnold, I.C.; Hitzler, I.; Muller, A. The immunomodulatory properties of Helicobacter pylori confer protection
against allergic and chronic inflammatory disorders. Front. Cell Infect. Microbiol. 2012. [CrossRef] [PubMed]
44. Kao, J.Y.; Zhang, M.; Miller, M.J.; Mills, J.C.; Wang, B.; Liu, M.; Eaton, K.A.; Zou, W.; Berndt, B.E.; Cole, T.S.;
et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced treg skewing and Th17
suppression in mice. Gastroenterology 2010, 138, 1046–1054. [CrossRef] [PubMed]
45. Amieva, M.R.; Vogelmann, R.; Covacci, A.; Tompkins, L.S.; Nelson, W.J.; Falkow, S. Disruption of the
epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003, 300, 1430–1434. [CrossRef]
[PubMed]
46. Weydig, C.; Starzinski-Powitz, A.; Carra, G.; Lower, J.; Wessler, S. CagA-independent disruption
of adherence junction complexes involves E-cadherin shedding and implies multiple steps in
Helicobacter pylori pathogenicity. Exp. Cell Res. 2007, 313, 3459–3471. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
